Anthem Biosciences IPO is a book-built issue IPO, aiming to raise ₹3,395.00 crore. It comprises a complete offer for sale of 5.96 crore equity shares. The bidding window was open from July 14, 2025, to July 16, 2025, with the IPO allotment to be finalised on July 17, 2025. Anthem Biosciences is scheduled to list on the BSE and NSE on July 21, 2025.
The IPO was priced at a range of ₹540-₹570 per share with a lot size of 26 shares. The public issue received bids for 2,81,49,30,794 shares against 4,17,50,321 shares available, resulting in an overall subscription of 67.42 times. QIBs led the response, subscribing 192.80 times their quota, followed by NIIs at 44.70 times.
Anthem Biosciences' ₹3,395.00 crore IPO, priced at a range of ₹540-₹570 per share, was subscribed 67.42 times overall. The IPO is a complete offer for sale of 5.96 crore equity shares. Bidding took place from July 14 to July 16, 2025, with the Anthem Biosciences IPO allotment status on July 17, 2025. Retail investors subscribed 5.98 and NIIs 44.70 times. Listing is expected on July 21, 2025.
The table below breaks down the Anthem Biosciences share allocation for different categories, highlighting the number of shares and their percentage of the total issue. However, the key focus remains on the quotas allocated to retail investors and HNIs, as they are the most relevant for individual investors.
| Investor Category | Shares Offered |
| QIB Shares Offered | 2,97,08,333 (49.87%) |
| − Anchor Investor Shares Offered | 1,78,24,999 (29.92%) |
| − QIB (Ex. Anchor) Shares Offered | 1,18,83,334 (19.95%) |
| NII (HNI) Shares Offered | 89,12,500 (14.96%) |
| − bNII > ₹10L | 59,41,667 (9.97%) |
| − sNII < ₹10L | 29,70,833 (4.99%) |
| Retail Shares Offered | 2,07,95,833 (34.91%) |
| Employee Shares Offered | 1,58,654 (0.27%) |
| Total Shares Offered | 5,95,75,320 (100.00%) |
Data Source: NSE
| Category | Subscription (times) |
| Qualified Institutional Buyers | 192.80 |
| Non-Institutional Investors | 44.70 |
| Retail Individual Investors | 5.98 |
| Total shares | 67.42 |
Note: The subscription details are as of July 16, 2025
Anthem Biosciences Limited is a technology-focused Contract Research, Development, and Manufacturing Organisation (CRDMO) with integrated operations across drug discovery, development, and commercial manufacturing.
Recognised as one of India’s few CRDMOs with both NCE (New Chemical Entity) and NBE (New Biological Entity) capabilities, the company serves a global clientele that includes emerging biotech firms and large pharmaceutical companies.
According to industry data, Anthem Biosciences became the fastest Indian CRDMO to reach ₹10,000 million in revenue within just 14 years, achieving this milestone in Fiscal 2021. It also recorded the highest revenue growth among peers in Fiscal 2023–24.
The company is known for its innovation across modalities such as RNAi, Antibody-Drug Conjugates (ADCs), peptides, lipids, and oligonucleotides. Manufacturing capabilities include custom synthesis, fermentation, flow chemistry, and biotransformation.
Know more about IPO allotment status and check your application details online for the latest updates on share allocation.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jul 16, 2025, 7:46 PM IST
Akshay Shivalkar
Akshay Shivalkar is a financial content specialist who strategises and creates SEO-optimised content on the stock market, mutual funds, and other investment products. With experience in fintech and asset management, he simplifies complex financial concepts to help investors make informed decisions through his writing.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
